« Back
Home /
Pirmitegravir

Pirmitegravir

Item no.	HY-130000-1ea
Manufacturer	MedChem Express
CASRN	2245231-10-9
Amount	1 ea
Quantity options	100 mg 10 mg 1 ea 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Molecules
Specific against	other
Formula	C27H31ClN4O3
Citations	[1]Maehigashi T, et al. A highly potent and safe pyrrolopyridine-based allosteric HIV-1 integrase inhibitor targeting host LEDGF/p75-integrase interaction site. PLoS Pathog. 2021;17(7):e1009671.
Smiles	O=C([C@H](C1=C(N=C(C2=C1C3=CC=C(C=C3)Cl)N(C(C)=C2C)CC4=CN(N=C4)C)C)OC(C)(C)C)O
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	STP0404
Available
Product Description	Pirmitegravir is a potent and first-in-class inhibitor of allosteric integrase (ALLINI) that targets LEDGF/p75 binding site. Pirmitegravir displays picomolar IC50 in human PBMCs with a >24, 000 therapeutic index against HIV-1. Pirmitegravir harbors outstanding anti-virus and safety properties[1].
Shipping	Room temperature
Manufacturers Applications	COVID-19-anti-virus
MolecularWeight	495.01
Clinical Information	Phase 2
Manufacturers Research Area	Infection
Solubility	10 mM in DMSO
Target	HIV; HIV Integrase
Manufacturers Target	HIV; HIV Integrase
Manufacturers Pathway	Anti-infection; Metabolic Enzyme/Protease
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 1 ea

available

Request delivery time